Executive Committee

The Executive Committee is comprised of scientific executives representing both U.S government agencies and industry. It is responsible for overseeing the activities and operations of the four working groups, including reviewing evaluations of experimental agents recommended for preclinical testing and clinical trials by the four working groups and the master protocols designed to test them


Gary Disbrow, Ph.D.
Biomedical Advanced Research and Development Authority, HHS

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President, Worldwide Research, Development and Medical

Gary Dubin, M.D.
President, Global Vaccine Business Unit
Takeda Pharmaceutical Co. Ltd.

Anthony Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases
National Institutes of Health

Gary Gibbons, M.D.
Director, National Heart, Lung, and Blood Institute
National Institutes of Health

Peter Marks, M.D., Ph.D.
Director, Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

William Pao, M.D., Ph.D. (Co-Chair)
Head of Pharma Research & Early Development

Lawrence A. Tabak, D.D.S., Ph.D. (Co-Chair)
Acting Director
National Institutes of Health

Janet Woodcock, M.D.
Principal Deputy Commissioner 
U.S. Food and Drug Administration

This page last reviewed on March 2, 2022